Key Takeaways
- • OrbiMed has raised $3 billion across new vehicles to invest in biotech and life sciences companies in the U.S., Europe and Asia, according to Fierce Biotech.
- • OrbiMed Asia Partners VI raised over $1 billion for healthcare growth equity and venture capital, up from $751 million for the fifth fund and $800 million for the fourth.
- • OrbiMed Private Investments X raised more than $1.9 billion for U.S. and European life science venture capital, slightly larger than its predecessor's $1.86 billion and up from $1.5 billion raised in 2021.
- • OrbiMed's current portfolio lists 22 Asian biopharma companies, reflecting interest that predates the recent surge in regional R&D activity.
- • Managing Partner Carl Gordon cited China's emergence as a biotechnology powerhouse, alongside AI and new therapeutic modalities, as drivers of opportunity.
Summary
OrbiMed has raised $3 billion to place a fresh round of investments in biotechnology and life sciences companies across the U.S., Europe and Asia, according to Fierce Biotech. The raise comes three years after OrbiMed closed its previous investment vehicles and expands the firm's capital base in Asia. Its Asia-focused fund, OrbiMed Asia Partners VI, raised over $1 billion to invest in healthcare growth equity and venture capital, compared with $751 million committed to the fifth fund and $800 million to the fourth.
The firm unveiled the Asian fund alongside the tenth iteration of its OrbiMed Private Investments vehicle, which has raised more than $1.9 billion to invest in U.S. and European life science venture capital. The publisher's background data notes that OrbiMed reported approximately $20 billion in assets under management as of 31 March 2026. Both funds will deploy capital across biopharma, medtech and technology-enabled healthcare services.
The Asia fund follows a broader wave of investor interest in the region's life sciences sector. Earlier in the month, TCGX raised $600 million for its first Asia life sciences fund and opened offices in Shanghai and Hong Kong. Fierce Biotech reports that China has become a major source of new drug candidates for Western pharmaceutical companies and a potential base for new global drugmakers. OrbiMed's current portfolio includes 22 Asian biopharma companies.
OrbiMed Managing Partner Carl Gordon attributed the opportunity to "China's emergence as a biotechnology powerhouse," and said "there has never been a more exciting time to invest in life sciences innovation." He also pointed to AI and the proliferation of therapeutic modalities as developments "expanding the opportunities to develop transformative treatments."
The U.S. biotech portfolio has recorded several exits recently. Forte Biosciences and Crinetics Pharmaceuticals accepted buyout offers worth $2.2 billion and $10 billion, respectively, in July. Over the following two months, Braveheart Bio, BlossomHill Therapeutics and ADARx Pharmaceuticals went public.
The firm unveiled the Asian fund alongside the tenth iteration of its OrbiMed Private Investments vehicle, which has raised more than $1.9 billion to invest in U.S. and European life science venture capital. The publisher's background data notes that OrbiMed reported approximately $20 billion in assets under management as of 31 March 2026. Both funds will deploy capital across biopharma, medtech and technology-enabled healthcare services.
The Asia fund follows a broader wave of investor interest in the region's life sciences sector. Earlier in the month, TCGX raised $600 million for its first Asia life sciences fund and opened offices in Shanghai and Hong Kong. Fierce Biotech reports that China has become a major source of new drug candidates for Western pharmaceutical companies and a potential base for new global drugmakers. OrbiMed's current portfolio includes 22 Asian biopharma companies.
OrbiMed Managing Partner Carl Gordon attributed the opportunity to "China's emergence as a biotechnology powerhouse," and said "there has never been a more exciting time to invest in life sciences innovation." He also pointed to AI and the proliferation of therapeutic modalities as developments "expanding the opportunities to develop transformative treatments."
The U.S. biotech portfolio has recorded several exits recently. Forte Biosciences and Crinetics Pharmaceuticals accepted buyout offers worth $2.2 billion and $10 billion, respectively, in July. Over the following two months, Braveheart Bio, BlossomHill Therapeutics and ADARx Pharmaceuticals went public.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.